Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE Together these data suggest a potential therapeutic benefit to combining an FGFR inhibitor with standard chemotherapeutic agents in endometrial cancer therapy particularly in patients with FGFR2 mutation positive tumors. 23060048 2012
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE The discovery of activating FGFR2 mutations in endometrial carcinoma raises the possibility of employing anti-FGFR molecularly targeted therapies in patients with advanced or recurrent endometrial carcinoma. 17525745 2007
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE AP24534 caused substantial reductions in ERK phosphorylation, PLCγ signaling and STAT5 signal transduction on ECs bearing FGFR2 activating mutations. 26574622 2016
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE These findings suggest that combinatory therapies using dovitinib plus ICI182.780 treatment can be truly effective in patients with endometrial carcinomas carrying FGFR2 mutations. 24448819 2014
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE However, AZD4547 has not been examined yet against FGFR2 mutant-driven endometrial cancers. 26294741 2015
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE Finally, the identification of 3 likely activating mutations in the tyrosine kinase receptor FGFR2, analogous to those reported in ovarian and endometrial carcinoma, point to potential therapeutic avenues for a subset of cases. 23778141 2013
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 Biomarker disease BEFREE The aim of this study was to examine the therapeutic potential of a rational drug combination based on the simultaneous targeting of mutant-FGFR2 and mTOR-driven signaling pathways in endometrial cancer cells. 23468082 2013
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE Our findings uncover collective cell polarity and invasion as common targets of disease-associated FGFR2 mutations that lead to poor outcome in endometrial cancer patients. 30002137 2018
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE We also observed a nonsignificant inverse association with rs889312 (MAP3K1) variant carriers [OR = 0.85 (95% CI: 0.68-1.05)] and rs1219648 (FGFR2) variant carriers [OR= 0.86 (95% CI: 0.69-1.06) and endometrial cancer risk. 18785201 2008
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE In tumor cell lines displaying molecular alterations in potential nintedanib targets, the inhibitor demonstrates direct antiproliferative effects: in the NSCLC cell line NCI-H1703 carrying a PDGFR<i>α</i> amplification (ampl.); the gastric cancer cell line KatoIII and the breast cancer cell line MFM223, both driven by a FGFR2 amplification; AN3CA (endometrial carcinoma) bearing a mutated FGFR2; the acute myeloid leukemia cell lines MOLM-13 and MV-4-11-B with FLT3 mutations; and the NSCLC adenocarcinoma LC-2/ad harboring a CCDC6-RET fusion. 29263244 2018
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 Biomarker disease BEFREE Combination of FGFR and AKT inhibition in an FGFR2-mutated endometrial cancer xenograft model enhanced modulation of transcript biomarkers from the PI3K/AKT pathway and tumor growth inhibition. 27550940 2016
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer. 30537101 2019
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE In vivo, dovitinib and NVP-BGJ398 significantly inhibited the growth of FGFR2-mutated endometrial cancer xenograft models. 23443805 2013
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 Biomarker disease BEFREE DNAs were extracted from 72 cases of fresh-frozen endometrial cancer tissues for FGFR2 mutational analysis by HRM analysis. 25517871 2015
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE Three of 43 (7%) endometrial carcinomas harbored FGFR2 exon 7 mutations. 21285871 2011
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 Biomarker disease BEFREE Mutations in multiple oncogenes including KRAS, CTNNB1, PIK3CA and FGFR2 have been identified in endometrial cancer. 22383975 2012
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 Biomarker disease BEFREE Mutational activation of one member of this receptor family, FGFR2, is a frequent event in endometrioid endometrial cancer. 20106510 2010
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE In addition, aberrant, ligand-free activation of the FGFR signaling pathway resulting from mutations in FGFR2 was also reported in endometrial cancer. 30963412 2019
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 AlteredExpression disease BEFREE Cytoplasmic expression of FGFR2 was higher in endometrial carcinoma when compared with the atrophic endometrium from the same patients (P=0.0283), but was lower in comparison with normal endometrium from women in the menstrual cycle. 21725289 2011
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE In vitro studies have shown that endometrial cancer cell lines with activating FGFR2 mutations are selectively sensitive to a pan-FGFR inhibitor, PD173074. 19243295 2009
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE Single nucleotide polymorphism, gene amplification or missense mutations of FGFR2 are associated with endometrial cancer. 30094104 2018
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 Biomarker disease BEFREE Here, we show that shRNA knockdown of FGFR2 or treatment with a pan-FGFR inhibitor, PD173074, resulted in cell cycle arrest and induction of cell death in endometrial cancer cells with activating mutations in FGFR2. 18757403 2008
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE Using Cox regression analysis adjusting for known prognostic factors, patients with FGFR2 mutation had significantly (p<0.025) shorter progression-free survival (PFS; HR 1.903; 95% CI 1.177-3.076) and endometrial cancer specific survival (ECS; HR 2.013; 95% CI 1.096-3.696). 28314589 2017
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 Biomarker disease BEFREE EC cell lines expressing wild-type FGFR2 were relatively resistant to all inhibitors, whereas EC cell lines expressing mutated FGFR2 showed differential sensitivity. 23908597 2013
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.700 GeneticVariation disease BEFREE Taken into account with our recent discovery of activating FGFR2 mutations in endometrial cancer, we suggest that FGFR2 may join the list of genes that play context-dependent opposing roles in cancer. 19147536 2009